The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Scientifically speaking, you’re right that is a breakthrough. Well done holders
Sounds like they’ve made some kind of a medical breakthrough . Great work Verici, not entirely sure what the so will make of it but it’s definitely positive news. Atb
Annual results due early june should lend some fuel to share price.
You must have one of them big DFS corner jobbies . Results tomorrow?
Yeah, I found some loose change behind the sofa.
Biggie
Nope.. he’s gone
Well done for selling that 100k Daniel! Hope not at too much of a loss . Atb
There are two key rules when investing in smallcaps. Firstly 'buy when there’s blood on the streets', & secondly ‘skate to where the puck is heading’.
Both of these apply to expert immunodiagnostics firm Verici Dx (Mrkcap £10m), who today announced a potentially break-through global licensing partnership with healthcare giant Thermo Fisher Scientific (Mrkcap $177bn) to exclusively develop an assay for pre-transplant kidney testing.
Here house broker Singer Capital Markets reckons the deal refers to Clarava. #VRCI’s 1st-in-class, blood test that allows doctors to identify those patients (pre graft) most likely to require increased monitoring - including adjustments in the type, dose & duration of immunosuppressants. Especially important when handling deceased donor parts which provide >60% of all organs.
Elsewhere the agreement also grants Thermo Fisher the sole right (but not obligation) to manufacture, distribute & sell the prognostic worldwide. Alongside providing it with access to a portion of #VRCI’s proprietary urine samples – further highlighting the value stored within its treasure trove of research assets.
In return Verici Dx will receive an upfront fee, augmented by staged payments dependent on operational deliverables (eg tech transfer & publications). Which in aggregate (assuming things go to plan) should equate to c.$5m over the next year with further instalments & ongoing royalties thereafter.
So what does this mean?
Well to me, the agreement not only represents another major endorsement of Verici Dx’s top notch science by an industry behemoth. But also the anticipated $5m should extend #VRCI’s cash run-way until at least the end of 2024 (source Singer Capital Markets), reduce costs and provide the Board with the option of perhaps moving deeper into this type of science-rich, capital-lite licensing model.
Which if adopted, would leverage the sales forces & supply chains of similar 3rd parties. Whilst equally enabling #VRCI to focus entirely on its unique IPR to drive better patient outcomes & material shareholder value.
In fact, this hypothetical arrangement would not be too dis-similar to Bioventix’s already successful licensing model, that is used to commercialise its monoclonal antibodies across the diagnostic sector.
Fantastic thanks for posting . Could show in the results soon
#VRCI
Although investors probably haven’t yet fully appreciated the upside offered by Verici Dx’s suite of clinically validated kidney transplant blood tests. It certainly appears the medical world is now waking up to the advantages of using these next generation immunodiagnostics.
In fact, hot on the heels of signing a global licensing partnership with healthcare giant Thermo Fisher Scientific (Mrkcap $200bn) in Nov'23 for Clarava, a 1st-in-class pre-transplant prognostic.
The company today said that the US Centers for Medicare & Medicaid Services (CMS) had confirmed a gap-fill price of $2,650 for both Tutivia (post-transplant test) & Clarava effective from 1st January 2024.
To me, this is a very encouraging step toward securing full reimbursement by Medicare, a national health insurance program covering 63.9m people. Indeed intuitively, if Medicare wasn’t planning to pay for these tests, then why would they waste the time/resource approving the price?
CEO Sara Barrington: "We are pleased that the pricing for both Tutivia and Clarava has been finalised at the proposed rates. This is another important milestone in our strategy to develop and commercialise a complementary suite of ground-breaking products that offer end-to-end testing for kidney transplant patients and their clinicians."
Elsewhere Verici Dx has also announced that its CLIA certified laboratory in Franklin (Tennessee, US) has been accredited by the internationally recognised College of American Pathology (CAP) following the completion of an on-site audit.
CAP accreditation is a hallmark of quality and excellence in clinical laboratory services and adds to #VRCI's existing portfolio of quality assurance awards and recognition.
COO Patti Connolly said: "We are pleased that our highly skilled laboratory team successfully achieved this accreditation with no deficiencies, findings, or recommendations identified during the audit. This accomplishment affirms our commitment to operating at the highest standards that healthcare providers, patients, and regulatory bodies expect."
Wrt the numbers, Singer Capital Markets have a 30p/share price target on the stock based on forecast 2024 revenues & adjusted EBITDA of $8.6m & $0.1m respectively.
Could well arrive earlier if good news. Just sayin
Results due early June so wait for that!
Would be good to see this close above 9.00+ today
In the top 50 risers ...yes smkr buys coming in strong rerating coming
See 10.00+ coming very soon
Maybe a positive update sooner than we think
Wow we are blue. this should never have been under 9. silly sellers robbed themselves in medium term imo
news will come, and cash runway until 2026.
remember where they’re at:
https://www.biopharma-reporter.com/Article/2023/11/16/Verici-Dx-receives-boost-with-Thermo-Fisher-licensing-deal
Well someone is 300k shares heavier this morning !
No progress report and we are in mid May beggars belief to be frank !
dear verici management.
please dont treat shareholders as "space ***** es "ie jeremy
clarkson
ie mushrooms .we invested in your cash call wholeheartdly and deserve the decency of being kept updated on progress.
Well that sure wasn’t a buy ! Didn’t move the sp though . Come on let’s be having some news
Not enough volume despite the odd large trade. It’s quite astonishing really, if they are buys then how the F can that not be insider trading of some description. We will see maybe they’re all sells and nothing will happen. Usually the opposite of what you want with AIM. Atb
More big buys surely we breakout now. News due anytime!
A bit of buying again .. hello company .. hello.. anyone there?